Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
language:"Undetermined"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=3
/vufind/Search/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=3
Search /vufind/Search2/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields&page=3
PubPharm (298)
21
Prophylactic Metformin After Antenatal Corticosteroids : Prophylactic Metformin After Antenatal Corticosteroids (PROMAC): A Double Blind Randomised Controlled Trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
22
Prophylactic Metformin After Antenatal Corticosteroids : Prophylactic Metformin After Antenatal Corticosteroids (PROMAC): A Double Blind Randomised Controlled Trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
23
Study of PF-06863135 Monotherapy and PF-06863135 + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of PF-06863135 Monotherapy And PF-06863135 + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone In Participants With Relapsed/Refractory Multiple Myeloma Who Have Received At Least 2 Prior Lines Of Therapy Including Lenalidomide And A Proteasome Inhibitor - MAGNETISMM-5
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
24
Study of PF-06863135 Monotherapy and PF-06863135 + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : An Open-Label, 3-Arm, Multicenter, Randomized Phase 3 Study To Evaluate The Efficacy And Safety Of PF-06863135 Monotherapy And PF-06863135 + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone In Participants With Relapsed/Refractory Multiple Myeloma Who Have Received At Least 2 Prior Lines Of Therapy Including Lenalidomide And A Proteasome Inhibitor - MAGNETISMM-5
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
25
NHOH-PTCL-GDPR : Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin (GDP) for Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma - NHOH-PTCL-GDPR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
26
NHOH-PTCL-GDPR : Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin (GDP) for Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma - NHOH-PTCL-GDPR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
27
W-JHS MM01 : Evaluation of efficacy and safety of a response adapted therapy adding bortezomib in newly diagnosed, transplant ineligible multiple myeloma patients with insufficient efficacy by lenalidomide - dexamethasone (Rd) therapy. - W-JHS MM01
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
28
W-JHS MM01 : Evaluation of efficacy and safety of a response adapted therapy adding bortezomib in newly diagnosed, transplant ineligible multiple myeloma patients with insufficient efficacy by lenalidomide - dexamethasone (Rd) therapy. - W-JHS MM01
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
29
A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
30
A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[30]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Sprache: Unbestimmt
Medienart
296
E-Ressourcen
286
Aufsätze
284
E-Artikel
12
Bücher
12
E-Books
2
Gedruckte Aufsätze
Alle anzeigen ...
weniger ...
Zeitschriftentitel
170
WHO International Clinical Trials Registry Plat...
114
Europäisches Patentamt
1
Journal of biomaterials and tissue engineering
1
Science of advanced materials
Thema
122
610
118
Study Type: Interventional
114
615
114
che
101
A61K
72
A61P
38
Recruitment Status: Authorised-recruitment may ...
36
Recruitment Status: Completed
30
Phase: Phase 3
20
Recruitment Status: Not yet recruiting
20
Recruitment Status: Recruiting
16
Medical Condition: MULTIPLE MYELOMA MedDRA vers...
13
Medium
9
A61K: Preparations for medical, dental, or toil...
8
A61M
8
Phase: Phase 1
6
C12N
6
Medical Condition: Atopic Dermatitis
6
Phase: Phase 2
6
Phase: Phase 4
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
157
2020-
141
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
Unbestimmt
Haven't found what you're looking for?
Wird geladen...